These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28689093)

  • 1. Immune checkpoint inhibitors and elderly people: A review.
    Daste A; Domblides C; Gross-Goupil M; Chakiba C; Quivy A; Cochin V; de Mones E; Larmonier N; Soubeyran P; Ravaud A
    Eur J Cancer; 2017 Sep; 82():155-166. PubMed ID: 28689093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy and elderly people: A review.
    Daste A; Chakiba C; Domblides C; Gross-Goupil M; Quivy A; Ravaud A; Soubeyran P
    Eur J Cancer; 2016 Dec; 69():199-215. PubMed ID: 27855351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of immune checkpoint inhibitors].
    Kitano S
    Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?
    Jackaman C; Nelson DJ
    Exp Gerontol; 2014 Jun; 54():53-7. PubMed ID: 24291067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
    Koster BD; de Gruijl TD; van den Eertwegh AJ
    Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung cancer, elderly and immune checkpoint inhibitors.
    Casaluce F; Sgambato A; Maione P; Spagnuolo A; Gridelli C
    J Thorac Dis; 2018 May; 10(Suppl 13):S1474-S1481. PubMed ID: 29951299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and efficacy of immune checkpoint inhibitors in elderly patients].
    Mailly-Giacchetti L; Lopez-Trabada D; Feldman J; André T; Cohen R
    Bull Cancer; 2023 Nov; 110(11):1204-1214. PubMed ID: 37679205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy].
    Hatae R; Chamoto K
    Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
    Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
    Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint modulation: rational design of combination strategies.
    Zamarin D; Postow MA
    Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Senant M; Giusti D; Weiss L; Dragon-Durey MA
    Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.
    Ciccarese C; Alfieri S; Santoni M; Santini D; Brunelli M; Bergamini C; Licitra L; Montironi R; Tortora G; Massari F
    Expert Opin Drug Metab Toxicol; 2016; 12(1):57-75. PubMed ID: 26565919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy comes of age: Immune aging & checkpoint inhibitors.
    Elias R; Karantanos T; Sira E; Hartshorn KL
    J Geriatr Oncol; 2017 May; 8(3):229-235. PubMed ID: 28223073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.